XKRX
256840
Market cap255mUSD
Jul 31, Last price
5,210.00KRW
1D
1.56%
1Q
25.85%
IPO
104.31%
Name
BNC Korea Co Ltd
Chart & Performance
P/E
26.78
P/S
3.99
EPS
194.57
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
89.23b
+10.16%
Net income
13.31b
-48.19%
CFO
16.70b
+1.63%
Profile
BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials in South Korea. The company offers HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration. It also provides Hibarry, a dressing for deep-cavity wounds that is used to reduce adhesion of the spinal cord during surgery; GENTA Q, a white collagen sponge, which is used to protect wounds by preventing contamination of wounds; and beauty solutions, face mask gels, mils cleansing foams, and brightening peeling gels. The company also exports its products to 45 countries. BNC Korea Co., Ltd. was founded in 2007 and is headquartered in Daegu, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY |
|---|---|---|
| 2024‑12 | 2023‑12 | |
| Income | ||
Revenues | 89,229,998 10.16% | 80,997,490 |
Cost of revenue | 59,042,162 | 57,565,895 |
Unusual Expense (Income) | ||
NOPBT | 30,187,835 | 23,431,595 |
NOPBT Margin | 33.83% | 28.93% |
Operating Taxes | 2,388,707 | (8,405,147) |
Tax Rate | 7.91% | |
NOPAT | 27,799,128 | 31,836,742 |
Net income | 13,307,623 -48.19% | 25,686,082 |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | 6,467,233 | (1,108) |
BB yield | ||
| Debt | ||
Debt current | 5,934,999 | 1,965,257 |
Long-term debt | 10,065,024 | 816,635 |
Deferred revenue | 704,982 | 704,982 |
Other long-term liabilities | 77,740 | 4,043,010 |
Net debt | (94,930,610) | (97,051,336) |
| Cash flow | ||
Cash from operating activities | 16,696,815 | 16,429,271 |
CAPEX | (14,453,162) | (8,250,989) |
Cash from investing activities | (12,456,817) | (43,855,692) |
Cash from financing activities | 15,635,268 | (18,176,306) |
FCF | 2,189,147 | |
| Balance | ||
Cash | 93,842,696 | 82,344,683 |
Long term investments | 17,087,936 | 17,488,546 |
Excess cash | 106,469,132 | 95,783,354 |
Stockholders' equity | (167,348,588) | (182,597,725) |
Invested Capital | 412,539,773 | 403,819,124 |
ROIC | 6.81% | 7.88% |
ROCE | 11.92% | 10.51% |
| EV | ||
Common stock shares outstanding | 67,759 | 67,508 |
Price | ||
Market cap | ||
EV | ||
EBITDA | 39,466,868 | 31,557,110 |
EV/EBITDA | ||
Interest | 334,383 | 679,662 |
Interest/NOPBT | 1.11% | 2.90% |